Hematology Frontier

Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, China, attracting hundreds of top experts and scholars in the field of hematology from both China and abroad. During the conference, "Hematology Frontier" specially invited Dr. Christian Chabannon from the Paoli-Calmettes Institute in Marseille, France, to discuss the strategies of personalized immunotherapy from a European perspective.

Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, attracting hundreds of top experts and scholars in the field of hematology from China and abroad. During the conference, Dr. Frédéric Millot from the University Hospital of Poitiers, France, was invited by "Hematology Frontier" to share the future directions in the treatment of chronic myeloid leukemia (CML) in children.

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lanfang Li from the Tianjin Medical University Cancer Institute and Hospital and Dr. Weiyun Zhuang from the University of California, San Francisco (UCSF) School of Medicine, to engage in a China-International dialogue, reviewing the latest treatment strategies for mycosis fungoides (MF) and Sézary syndrome (SS).

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lihua Qiu from Tianjin Medical University Cancer Institute and Hospital and Dr. Swaminathan Iyer from The University of Texas MD Anderson Cancer Center to engage in a China-International dialogue, reviewing the latest therapeutic advances in peripheral T-cell lymphoma (PTCL) and the optimization direction of treatment strategies.

From September 25 to September 29, the 27th National Clinical Oncology Conference and CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen. During the conference, Hematology Frontier invited Dr. Zhiming Li from Sun Yat-sen University Cancer Center to share his strategies for treating diffuse large B-cell lymphoma (DLBCL).

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the premier global oncology conferences, it brought together experts and scholars from around the world to share cutting-edge research and chart future directions. During the conference, Dr. Junmin Song from the Jacobi Medical Center, Albert Einstein College of Medicine, presented the first real-world study comparing BCMA CAR-T therapy with bispecific antibodies in the treatment of multiple myeloma (802MO). This presentation garnered significant attention from attendees. Hematology Frontier invited Dr. Song to provide an in-depth interpretation of the study and to discuss the future prospects of these two innovative therapies in multiple myeloma treatment.

From September 25 to 28, 2024, the 21st International Myeloma Society (IMS) Annual Meeting was held in Rio de Janeiro, Brazil. At this prestigious conference, the research led by Dr. Juan Li from The First Affiliated Hospital of Sun Yat-sen University in China was selected for poster presentation. The study suggests that for high-risk multiple myeloma (MM) patients with dual hits of 1q21 amplification and t(4;14), tandem autologous stem cell transplantation (Tandem ASCT) might be an effective treatment strategy. Hematology Frontier invited Professor Li to share the findings of this study and its clinical significance.

From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in the development of clinical oncology in China, with numerous experts and scholars contributing to and benefiting from CSCO’s growth. In response to CSCO's initiative, Hematology Frontier established the Growing with CSCO column to look back at the history of this organization alongside Chinese scholars. This issue features an exclusive interview with Dr. Jun Zhu, Vice President of the CSCO Council and Professor at Peking University Cancer Hospital, where he shares his journey of growing with CSCO and highlights the progress and achievements in the field of lymphoma in China.

The 2024 Nobel Prize in Physiology or Medicine has once again brought the spotlight onto the field of gene regulation. This year, American scientists Victor Ambros and Gary Ruvkun were honored with the prestigious award for their pioneering research on microRNA and its role in post-transcriptional gene regulation. Their groundbreaking discoveries not only opened new horizons in understanding gene regulation but also offered new perspectives and methods for studying and treating hematological diseases such as leukemia.